CorWave

CorWave is a private, clinical-stage medical device company pioneering a novel wave membrane technology to create pulsatile LVADs, a significant departure from the continuous-flow pumps that dominate the current market. Inspired by natural blood flow patterns, its technology aims to improve patient outcomes and quality of life by reducing complications associated with non-pulsatile flow. With a seasoned leadership team and over 90 employees, the company is advancing its lead product, the CorWave LVAS Nemo, through clinical development to address the large and growing unmet need in advanced heart failure.

Proprietary 'wave membrane' technology that generates a pulsatile, undulating motion to pump blood, designed to mimic natural flow and improve hemocompatibility compared to standard rotary pump LVADs.

The LVAD market is an oligopoly dominated by Abbott (HeartMate 3) and Medtronic (HVAD, though recently discontinued). Competition is based on device reliability, hemocompatibility, and clinical outcomes. CorWave's primary competitive differentiation is its pulsatile flow, which, if proven clinically superior, could disrupt the continuous-flow paradigm established over the last decade.